Paper Details

  1. Home
  2. Paper Details

A randomized, placebo-controlled crossover trial of phentermine-topiramate ER in patients with binge-eating disorder and bulimia nervosa.

Author: AdlerSarah, BentleyJason P, DalaiShebani Sethi, NajarianThomas, PajaritoSarah, SaferDebra L, ToyamaHannah

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This study investigated the efficacy and safety of phentermine/topiramate ER (PHEN/TPM-ER) for binge eating disorder (BED) or bulimia nervosa (BN) in a crossover randomized controlled trial.
Paper Details　
Original Abstract of the Article :
Open trials suggest phentermine/topiramate ER (PHEN/TPM-ER), food and drug administration (FDA) approved for obesity, has utility for binge eating. With no randomized controlled trials (RCTs) yet performed, this trial aimed to evaluate PHEN/TPM-ERs efficacy and safety in a crossover RCT for patients...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/eat.23192

データ提供：米国国立医学図書館（NLM）

Phentermine/Topiramate ER for Binge-Eating Disorder and Bulimia Nervosa: A Promising Oasis in the Desert of Eating Disorders

Eating disorders are like a vast desert, leaving individuals feeling lost and parched. This research explores the potential of phentermine/topiramate ER (PHEN/TPM-ER), a medication typically used for obesity, as a potential oasis for individuals struggling with binge-eating disorder (BED) and bulimia nervosa (BN). The study aimed to evaluate the efficacy and safety of PHEN/TPM-ER in a randomized controlled crossover trial for patients with BED or BN, filling a gap in the existing literature.

A Ray of Hope: PHEN/TPM-ER Shows Potential for Binge-Eating Disorders

The research results suggest a potential oasis of relief for those battling binge-eating disorders. While the study was small, the findings are promising, demonstrating the potential for PHEN/TPM-ER to effectively manage BED and BN. Further research is needed to confirm these findings and fully understand the therapeutic potential of this medication.

Navigating the Desert of Eating Disorders: Seeking Help and Exploring Options

Navigating the desert of eating disorders can be a challenging journey. Seeking help from a qualified healthcare professional is crucial for developing a comprehensive treatment plan that addresses the underlying issues. Exploring all available options, including medications and therapies, can help individuals find the most effective path to recovery.

Dr.Camel's Conclusion

This research offers a glimmer of hope in the desert of eating disorders. While more research is needed to confirm its effectiveness, PHEN/TPM-ER shows promise as a potential treatment option for BED and BN. As a camel who has encountered many weary travelers in the desert, I am encouraged by the potential for new and effective treatments to alleviate the suffering caused by these complex conditions.

Date :
  1. Date Completed 2020-06-30
  2. Date Revised 2023-08-27
Further Info :

Pubmed ID

31721257

DOI: Digital Object Identifier

10.1002/eat.23192

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.